GgoogleMX first seen 3 d ago, last 13 h ago, peak #1
Bayer rises despite analyst caution after Kerendia milestone
Original: bayer
Bayer shares have moved higher even as several analysts cut their expectations for the company. The lift follows news that Bayer reached a milestone in the United States for expanding the approved uses of Kerendia, one of its key kidney-disease drugs. Markets in Germany and Latin America are tracking the stock's move, with investors weighing the positive drug-development news against more cautious analyst outlooks.
Why now: Positive regulatory news on Kerendia is driving the stock up at the same time analysts are lowering forecasts, creating debate over Bayer's outlook.
Rank over time, top of the chart is #1. 2 snapshots from 14 h ago to 13 h ago.
Evidence
- Bayer steigt – während Analysten ihre Erwartungen kappen · Investing.com Deutsch
- Bayer erreicht Meilenstein bei der Ausweitung der Kerendia-Indikation in den USA · MarketScreener Deutschland
Elsewhere
API: https://socialmediatrends-api.osmike.com/v1/trends/1746560